Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CARPROFEN
Norbrook Laboratories Limited
QM01AE91
CARPROFEN
20 mg/tablet
Tablets
POM
Canine
Carprofen
N.S.A.I.D
Authorised
2003-07-25
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Carprieve 20 mg Tablets for Dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: _ACTIVE SUBSTANCE:_ Carprofen 20 mg _EXCIPIENTS:_ For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets: A white/off white circular tablet with a break line on one face and “20” scored on the opposing face. The tablets can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For analgesia and reduction of chronic inflammation in musculoskeletal disturbances in dogs, for example in degenerative joint disease. 4.3 CONTRAINDICATIONS Use of this product in cats is contra-indicated. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Refer to statements under Sections 4.3 and 4.5 HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 28/11/2014_ _CRN 7019477_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS: Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concu Read the complete document